drugset / Trial / NCT04092647

Ashwagandha for Cognitive Dysfunction

NCT04092647

Phase 2 Unknown 80 enrolled Sutter Health
RandomizedCrossoverDouble-blindTreatment

Summary

This is a 1:1 randomized double blinded placebo controlled trial. • To determine if ashwagandha can improve cognitive dysfunction when compared with placebo in patients undergoing chemotherapy for cancer.

Timeline

Start
2023-01-01
Primary completion
2024-12-31
Completion
2025-07-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ashwagandha Traditional medicine (herbal / TCM) 350 mg Oral